GOSS vs. SABS
GOSS (Gossamer Bio, Inc.) and SABS (SAB Biotherapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, GOSS returned -53.34%/yr vs -48.82%/yr for SABS. At a 0.12 correlation, their price movements are largely independent.
Performance
GOSS vs. SABS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GOSS achieves a -93.93% return, which is significantly lower than SABS's -6.95% return.
GOSS
- 1D
- -5.94%
- 1M
- -46.26%
- YTD
- -93.93%
- 6M
- -94.49%
- 1Y
- -84.57%
- 3Y*
- -47.62%
- 5Y*
- -53.34%
- 10Y*
- —
SABS
- 1D
- 1.16%
- 1M
- 0.29%
- YTD
- -6.95%
- 6M
- -4.40%
- 1Y
- 81.25%
- 3Y*
- -27.59%
- 5Y*
- -48.82%
- 10Y*
- —
GOSS vs. SABS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GOSS Gossamer Bio, Inc. | -93.93% | 242.69% | -0.87% | -57.95% | -80.81% | 5.70% |
SABS SAB Biotherapeutics, Inc. | -6.95% | -1.43% | -44.81% | 16.55% | -92.45% | -23.05% |
Correlation
The correlation between GOSS and SABS is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Feb 10, 2021 | 0.12 |
Fundamentals
GOSS:
$44.09M
SABS:
$186.38M
GOSS:
-$0.79
SABS:
-$0.01
GOSS:
$55.54M
SABS:
$0.00
GOSS:
$38.36M
SABS:
-$2.35M
GOSS:
-$171.46M
SABS:
$994.59K
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GOSS vs. SABS — Risk / Return Rank
GOSS
SABS
GOSS vs. SABS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Gossamer Bio, Inc. (GOSS) and SAB Biotherapeutics, Inc. (SABS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GOSS | SABS | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.66 | 0.98 | -1.63 |
Sortino ratioReturn per unit of downside risk | -0.47 | 1.91 | -2.38 |
Omega ratioGain probability vs. loss probability | 0.92 | 1.24 | -0.32 |
Calmar ratioReturn relative to maximum drawdown | -0.89 | 2.38 | -3.27 |
Martin ratioReturn relative to average drawdown | -1.65 | 5.38 | -7.02 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GOSS | SABS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.66 | 0.98 | -1.63 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.52 | -0.44 | -0.08 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.50 | -0.43 | -0.06 |
Drawdowns
GOSS vs. SABS - Drawdown Comparison
The maximum GOSS drawdown since its inception was -99.30%, roughly equal to the maximum SABS drawdown of -99.01%. Use the drawdown chart below to compare losses from any high point for GOSS and SABS.
Loading charts...
Drawdown Indicators
| GOSS | SABS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.30% | -99.01% | -0.29% |
Max Drawdown (1Y)Largest decline over 1 year | -95.03% | -33.80% | -61.23% |
Max Drawdown (3Y)Largest decline over 3 years | -95.03% | -88.96% | -6.07% |
Max Drawdown (5Y)Largest decline over 5 years | -98.73% | -99.01% | +0.28% |
Current DrawdownCurrent decline from peak | -99.30% | -96.90% | -2.40% |
Average DrawdownAverage peak-to-trough decline | -71.38% | -78.01% | +6.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 51.26% | 14.94% | +36.32% |
Volatility
GOSS vs. SABS - Volatility Comparison
Gossamer Bio, Inc. (GOSS) has a higher volatility of 62.06% compared to SAB Biotherapeutics, Inc. (SABS) at 21.11%. This indicates that GOSS's price experiences larger fluctuations and is considered to be riskier than SABS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GOSS | SABS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 62.06% | 21.11% | +40.95% |
Volatility (6M)Calculated over the trailing 6-month period | 182.68% | 44.51% | +138.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 129.41% | 83.68% | +45.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 103.05% | 111.96% | -8.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 93.59% | 108.66% | -15.07% |
Dividends
GOSS vs. SABS - Dividend Comparison
Neither GOSS nor SABS has paid dividends to shareholders.
Financials
GOSS vs. SABS - Financials Comparison
This section allows you to compare key financial metrics between Gossamer Bio, Inc. and SAB Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GOSS and SABS have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GOSS has higher volatility (62.06%) compared to SABS (21.11%). In terms of maximum drawdown, GOSS dropped -99.30% vs SABS's -99.01%.
SABS currently has the higher Sharpe Ratio (0.98 vs -0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GOSS and SABS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer